Member Info for inanaco

I wonder what prompted that House move ...

like Boris and Corbyn ... lol

you are contradicting earlier posts .

a statement by Ivy ............

"""""The BOD could easily update the market but chooses not to but that is their choice.
This has become a share where the only ones who make profit are the traders and the stale bulls with much higher averages largely suffer but still confident that we will get there but I will enjoy the journey much more elsewhere than here ATM."""

says it all ...

the issue you have as does knowlesi

Jamesbond007 ... or Mick .. was with me at the 2015 AGM "non of the claims that you have made" happened ..

otherwise this BB would have read all about it , back in 2015 .. and nobody has posted to that effect ...

you are on your own Ivy

Ivy

strikes me you lost so much capital in MTFB this prompted you to take the hit in scancell as well ....

and you have moved on ...

Ivy do you remember the hell fire and brimstone posts you did against mine on the VAL bb ...

look at the SP now ...

i was spot on about that share

another one

"""As for MTFB I really don’t know why you keeping on bringing it up as the only thing I am guilty of is doing exactly what you have done on here ie being confident in the outcome and having contact with the CEO.""""

no the difference here is when folks asked me about MTFB i explained it was not a good investment and i gave the reasons why ..

some listened to the alternative view Ivy ... you and Bermuda went ballistic over that !!

more quotes

"""" Yes my initial buys on here were probably 27-28p but I scaled in and also sold sone at a loss as the SP dropped. """"

"""" yes I failed Biology o level but turned down the chance to do several PhDs """
""As for numbers of PhDs it us irrelevant.PhDs are 2 a penny in any lab setting""
""""Now having likes of LD is much more important imo than quantity of PhDs as it is the experts that lead to the breakthroughs not the general lab folk.""""

plenty of Alternative views

so am i ... LOL

I agree ... C7 ... but Ruck has this post sitting as a problem he never dealt with

==============================================================================================

Inan, not scoffing at all. It is quite possible, in my opinion not likely but perhaps others feel differently.

I posted the calculation on ADVFN but in case you missed it here it is again:

Anyway, here's how we can get to £8

All platforms SCIB1, SCIB2, MODI1 successfully through trials
Each target grabs 25% market share (TD reckon 11%)
Royalty on each treatment 24% (TD reckon 17.5%, 15% for SCLC with CRUK cut)
Net profit 22% (that would be good going)

Will need at least 2 additional funding rounds raising £16M at average 9p
PE of 20

= SP of £8.15

This would be an NPV of £4.10 if was achieved in 3 years.
Would be NPV of 72p if it takes 10 years.

one day we are vulnerable to a Take over ..
then it moves to being vulnerable to a funding round

i wish the back seat BOD would make up there mind ...

they probably are Ruck ...

Unfortunately You are not invited to comment at BOD level and you have no idea what is going on behind closed doors as you are on the outside

https://www.nature.com/articles/s41417-018-0012-7

point i am trying to make here ..

Moditoppe is like an On Off switch ...

if it works it will produce spectacular results ...

Modi1 (amplivant) an insight can be seen by other scientific papers ...

Scvancell Cd4 + T cell skewed to TH1

read this

In summary, T-bet skewed the response of CD4+ B7H6-specific CAR T cells to secrete more proinflammatory and Th1 cytokines, while reducing the amount of Th2 cytokines when stimulated with B7H6-expressing tumors. The T-box domain of the T-bet gene was not critical for several of the phenotypic and functional differences, rather data suggest it aids in amplifying the CAR T cells’ response which has translated into an effective response in a suboptimal treatment against a mouse lymphoma. In conclusion, CAR T cells overexpressing T-bet can be used to enhance CAR T cell therapy against cancer.

now read that again .........

It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system.

missing "may"
Missing "Might"

C7 ... leave the funding issue to Lozan .. LOL trust me .. he is the expert in explaining to the market with support from Ivy ,ONW etc
Those of us that have actually run corporate structures are well aware of the importance of Funding ....

however its easy if you have the right data that is "Viable" hence Diggles did commit .. after Due Diligence

Scancell funding route has now changed because we have exhausted the EIS route. We have now entered mainstream however we have specific targeted funds because we are so close to trials.

whats fascinating is just how much development work is being done by Scancell on TCR , don't underestimate the value of that increase in the IP ..

the other day i posted a link .. on homocitrulline but hardly any one "clocked" the value of that .... which absolutely backed up

Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

source of funding .... impossible to predict at this stage, its to early

If by July we have not signed up with BioNtech then it may be a Stockmarket raise becomes inevitable ...

but its only February

Group cash balance at 31 October 2019 was £5.79 million

if this program was dead

why mention it ???

https://www.scancell.co.uk/Data/Sites/1/media/docspres/presentation-to-lsx-world-congress-february-2020.pdf

Funding ... Its to early to consider